Реферат
ABSTRACT Purpose: To investigate the potential effects of chronic exposure to a nasal decongestant and its excipients on ocular tissues using an experimental rat model. Methods: Sixty adult male Wistar rats were randomized into six groups. The first two groups were control (serum physiologic) and Otrivine® groups. The remaining four groups received the Otrivine excipients xylometazoline, benzalkonium chloride, sorbitol, and ethylene diamine tetra acetic acid. Medications were applied into both nostrils twice a day for 8 weeks. Before the rats were sacrificed, epithelial staining, the Schirmer test, and intraocular pressure measurements were performed under ketamine/xylasine anesthesia (50 and 5 mg/kg, respectively). Results: Epithelial defects and dry eye were common findings in all study groups. Cataracts developed in two cases clinically. Histopathological evaluation revealed many different pathological alterations in all parts of the ocular tissues such as corneal edema, polypoid proliferation and hyalinization of the vessel wall, cystic formation of the lens, retinal nerve fiber layer degeneration, and corpora amylacea formation of the lacrimal gland. Conclusions: Prolonged usage of the nasal decongestant xylometazoline and its excipients may cause ophthalmic problems such as dry eyes, corneal edema, cataracts, retinal nerve fiber layer, and vascular damage in rats. Although these results were obtained from experimental animals, ophthalmologists should keep in mind the potential ophthalmic adverse effects of this medicine and/or its excipients and exercise caution with drugs containing xylometazoline, ethylene diamine tetra acetic acid, benzalkonium chloride and sorbitol for patients with underlying ocular problems.
RESUMO Objetivo: Investigar os possíveis efeitos da exposição crônica de descongestionante nasal e seus excipientes em tecidos oculares, utilizando um modelo experimental com ratos. Métodos: Sessenta ratos Wistar adultos machos foram divididos aleatoriamente em seis grupos. Os primeiros dois grupos foram controle (soro fisiológico) e Otrivina®. Os quatro grupos restantes receberam os excipientes de Otrivina, tais como Xilometazolina, Benzalcônio, Sorbitol e Ácido Etilenodiamino Tetracético (EDTA). Os medicamentos foram aplicados em ambas as narinas dos ratos, duas vezes ao dia, durante 8 semanas. Antes que os ratos fossem sacrificados, a coloração epitelial, o teste de Schirmer e a medida da pressão intraocular foram realizados sob anestesia com Ketamina/Xilasina (50 e 5 mg/kg, respectivamente). Resultados: Defeitos epiteliais e olho seco foram achados comuns nos grupos de estudo. A catarata desenvolveu-se clinicamente em dois casos. A avaliação histopatológica revelou a existência de alterações em todas as partes dos tecidos oculares, tais como edema de córnea, proliferação polipoide e hialinização da parede vascular, formação cística da lente, degeneração da camada de fibra nervosa da retina (RNFL) e formação de corpos amiláceos da glândula lacrimal. Conclusões: O uso prolongado do descongestionante nasal Xilometazolina e seus excipientes pode causar vários problemas oftalmológicos, como olho seco, edema de córnea, catarata, RNFL e dano vascular em ratos. Embora esses resultados tenham sido obtidos a partir de animais experimentais, os oftalmologistas devem ter em mente os potenciais efeitos oftalmológicos adversos desse medicamento e/ou de seus excipientes.
Тема - темы
Animals , Male , Nasal Decongestants/adverse effects , Eye/drug effects , Eye Diseases/chemically induced , Imidazoles/adverse effects , Nasal Mucosa/drug effects , Benzalkonium Compounds/adverse effects , Severity of Illness Index , Random Allocation , Edetic Acid/adverse effects , Rats, Wistar , Disease Models, Animal , Eye/pathology , Eye Diseases/pathology , Intraocular Pressure , Nasal Mucosa/pathologyРеферат
Abstract The aim of this study was to assess the imaging and histological features of experimental periapical lesions, including the adjacent alveolar bone, in rats under zoledronic acid treatment. The study used 40 male Wistar rats distributed into 8 groups of 5 animals each: G1: induction of periapical lesion (PL) and weekly intraperitoneal administration (WIPA) of saline solution (0.9% NaCl) for 4 weeks; G2: PL induction and WIPA of zoledronic acid (0.15 mg/kg/week) for 4 weeks; G3: PL induction and WIPA of saline solution for 8 weeks; G4: PL induction and WIPA of zoledronic acid for 8 weeks; G5:WIPA of saline solution for 4 weeks and subsequent PL induction; G6: WIPA of zoledronic acid for 4 weeks and subsequent PL induction; G7: WIPA of saline solution for 8 weeks and subsequent PL induction; G8: WIPA of zoledronic acid for 8 weeks and subsequent PL induction. The administration of zoledronic acid or saline solution continued after PL induction until the euthanasia. Thus, cone beam computed tomography and histological analysis were performed. Statistical analyzes were performed by ANOVA and Kruskal-Wallis test. Groups treated with zoledronic acid showed significantly smaller size of PL than the groups treated with 0.9% NaCl (p<0.05). PLs were formed by chronic inflammation ranging from mild to moderate, with no difference between groups. In all specimens, no mandibular necrosis was observed. In conclusion, the presence of PLs apparently does not represent an important risk factor for the development of bisphosphonate-related osteonecrosis of the jaws.
Resumo O objetivo deste estudo foi avaliar as características histológicas e de imagem de lesões periapicais experimentais, incluindo o osso alveolar adjacente, em ratos sob tratamento com ácido zoledrônico. O estudo utilizou 40 ratos Wistar, machos, distribuídos em 8 grupos de animais cada: G1: indução de lesão periapical (LP) e administração intraperitoneal semanal (AIS) de solução salina (NaCl 0.9%) por 4 semanas; G2: indução de LP e AIS de ácido zoledrônico (0,15 mg/kg/week) por 4 semanas; G3: indução de LP e AIS de solução salina por 8 semanas; G4: indução de LP e AIS de ácido zoledrônico por 8 semanas; G5- AIS de solução salina por 4 semanas e subsequente indução de LP; G6- AIS de ácido zoledrônico por 4 semanas e subsequente indução de LP; G7: AIS de solução salina por 8 semanas e subsequente indução de LP; G8: AIS de ácido zoledrônico por 8 semanas e subsequente indução de LP. A administração de ácido zoledrônico ou solução salina continuou após indução de LP até a eutanásia. Após isso, tomografia computadorizada de feixe cônico e análise histológica foram realizadas. Análises estatísticas foram realizadas por ANOVA e teste de Kruskal-Wallis. Os grupos tratados com ácido zoledrônico mostraram LPs significativamente menores que os grupos tratados com NaCl 0.9% (p <0.05). LPs eram formadas por inflamação crônica variando de leve a moderada, sem diferença entre os grupos. Em todos os espécimes, necrose mandibular não foi observada. Em conclusão, a presença de LPs aparentemente não representa um fator de risco importante para o desenvolvimento de osteonecrose relacionada ao uso de bisfosfonatos.
Тема - темы
Animals , Male , Rats , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Imidazoles/adverse effects , Periapical Diseases/diagnostic imaging , Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging , Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology , Periapical Diseases/chemically induced , Periapical Diseases/pathology , Rats, WistarРеферат
Abstract: Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclatasvir without ribavirin for the treatment of hepatitis C virus (HCV) recurrence after liver transplantation (LT) in both HCV-monoinfected and human immunodeficiency virus (HIV)-HCV coinfected patients. Material and methods. We retrospectively evaluated 22 consecutive adult LT recipients (16 monoinfected and 6 coinfected with HIV) who received a 24-week course of sofosbuvir plus daclatasvir treatment under an international compassionate access program. Results. Most patients were male (86%), with a median age of 58 years (r:58-81y). Median time from LT to treatment onset was 70 months (r: 20-116 m). HCV genotype 1b was the most frequent (45%), 55% had not responded to previous treatment with Peg-INF and RBV and 14% to regiments including first generation protease inhibitors. Fifty-six percent of the patients had histologically proven cirrhosis and 6 had ascites at baseline. All patients completed the 24-week treatment course without significant side effects except for one episode of severe bradicardya, with only minor adjustments in immunosuppressive treatment in some cases. Viral suppression was very rapid with undetectable HCV-RNA in all patients at 12 weeks. All 22 patients achieved a sustained virological response 12 weeks after treatment completion. Conclusion. The combination of sofosbuvir plus daclatasvir without ribavirin is a safe and effective treatment of HCV recurrence after LT in both monoinfected and HIV-coinfected patients, including those with decompensated cirrhosis.
Тема - темы
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Antiviral Agents/administration & dosage , HIV Infections/virology , Liver Transplantation/adverse effects , Hepatitis C/drug therapy , Hepacivirus/drug effects , End Stage Liver Disease/surgery , Coinfection , Sofosbuvir/administration & dosage , Imidazoles/administration & dosage , Liver Cirrhosis/drug therapy , Antiviral Agents/adverse effects , Recurrence , Time Factors , Virus Activation , RNA, Viral/genetics , Drug Administration Schedule , HIV Infections/diagnosis , Retrospective Studies , Treatment Outcome , Hepatitis C/diagnosis , Hepatitis C/virology , Hepacivirus/genetics , Hepacivirus/pathogenicity , Viral Load , Drug Therapy, Combination , Compassionate Use Trials , End Stage Liver Disease/diagnosis , End Stage Liver Disease/virology , Sofosbuvir/adverse effects , Imidazoles/adverse effects , Immunosuppressive Agents/administration & dosage , Liver Cirrhosis/diagnosis , Liver Cirrhosis/virologyРеферат
Abstract: Background. Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries. Aim. To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients. Material and methods. Sixty-one patients with HCV genotype 1b were enrolled in the Turkish early access program. Most of the patients were in difficult-to-treat category. Patients were visited at each 4 week throughout the follow-up period. Laboratory findings and adverse events were recorded at each visit. Results. Fifty-seven of 61 enrolled patients completed 24 weeks of treatment. Two patients died as a result of underlying diseases at 12-14th weeks of treatment. Two patients stopped the treatment early as a consequence of virological breakthrough, and 2 patients had viral relapse at the post-treatment follow-up. Overall SVR12 rates were 90% (55/61) and 93.2% (55/59) according to intention-to-treat (ITT) and per protocol (PP) analysis respectively. In ITT analysis, SVR12 was achieved by 93% (13/14) in relapsers, 80% (12/15) in interferon-ineligible patients and 91% (20/22) in previous nonresponder patients. SVR12 rates were 86.5% and 91.4% in patients with cirrhosis according to ITT and PP analysis respectively. SVR12 was 95.8% in non-cirrhosis group in both analysis. Patients with previous protease inhibitor experience had an SVR12 of 87.5%. Common adverse events developed in 28.8% of patients. There were no treatment related severe adverse event or grade-4 laboratory abnormality. Conclusions. Daclatasvir and asunaprevir dual therapy is found to be effective and safe in difficult-to-treat Turkish patients with HCV genotype 1b infection.
Тема - темы
Humans , Male , Female , Middle Aged , Aged , Antiviral Agents/therapeutic use , Sulfonamides/therapeutic use , Hepacivirus/drug effects , Hepatitis C, Chronic/drug therapy , Health Services Accessibility , Imidazoles/therapeutic use , Isoquinolines/therapeutic use , Antiviral Agents/economics , Antiviral Agents/adverse effects , Sulfonamides/economics , Sulfonamides/adverse effects , Time Factors , Turkey , RNA, Viral/genetics , Program Evaluation , Treatment Outcome , Drug Costs , Cost-Benefit Analysis , Hepacivirus/genetics , Viral Load , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/economics , Hepatitis C, Chronic/virology , Drug Therapy, Combination , Genotype , Health Services Accessibility/economics , Imidazoles/economics , Imidazoles/adverse effects , Isoquinolines/economics , Isoquinolines/adverse effectsРеферат
ABSTRACT PURPOSE : To evaluate a modified experimental model for medication-related osteonecrosis of the jaw (MRONJ) through the upper right central incisor extraction followed by intravenous bisphosphonate administration. METHODS: Forty five rats underwent the upper right central incisor tooth extraction were divided in 2 groups: Group I - experimental group, 30 rats received an intravenous administration protocol of zoledronic acid 35μg/kg into the tail vein every two weeks, totalizing four administrations, during eight weeks of administration, previously the extraction, and Group II - control group, 15 rats didn't received any medication before extraction. The groups were subdivided in postoperative periods: 14/28/42 days. Clinical analysis and microtomography were performed to verify the presence of osteonecrosis. In addition, descritive histological analysis of hematoxylin-eosin stained sections was performed to evaluate the presence of osteonecrosis or necrotic foci. RESULTS: Twelve (40%) rats, from experimental group, showed clinical signs of MRONJ (p=0.005), however, all samples showed imaginologic findings like osteolysis and loss of integrity of the cellular walls (p≤0.001). Microscopic evaluation revealed osteonecrosis areas with microbial colonies and inflammatory infiltrate (p≤0.001). In the control group, all animals presented the chronology of a normal wound healing. CONCLUSIONS: The presence of medication-related osteonecrosis of the jaw after maxillary central incisor extraction in rats. This new experimental model may be considered an option for the study of MRONJ.
Тема - темы
Animals , Male , Models, Animal , Diphosphonates/administration & dosage , Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology , Imidazoles/administration & dosage , Osteitis/pathology , Osteolysis/chemically induced , Osteolysis/diagnostic imaging , Tooth Extraction/adverse effects , Tooth Extraction/methods , Maxillary Diseases/diagnostic imaging , Alveolar Bone Loss/diagnostic imaging , Rats, Wistar , Diphosphonates/adverse effects , X-Ray Microtomography/instrumentation , Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging , Administration, Intravenous/methods , Imidazoles/adverse effects , Incisor/surgeryРеферат
Bisphosphonate-related osteonecrosis of the jaws (BROJ) has been described since 2003 as an adverse effect of bisphosphonate medications. These drugs act on the vasculature and bone remodeling, mainly on osteoclastic activity and can cause areas of necrotic bone exposure. Treatment for the BROJ is not yet defined, but surgical treatment is one of the forms proposed, which may cause oral deformities like sinus communication in some cases. In situations like this the buccal fat pad is an important alternative for coating nasal-oral communications, due its large blood supply, elasticity, absence of restriction by age and safety. This paper presents the case of a 58-year-old woman with BROJ in the left maxilla caused by the use of zoledronic acid for metastatic breast cancer. The extensive necrotic bone area was surgically removed resulting in oral sinus communication. A buccal fat pad was used to cover the defect. More studies should be performed regarding the treatment of BROJ but, if necessary, a buccal fat pad flap could be an alternative to solve nasal-oral communications related to BROJ.
Osteonecrose dos maxilares por bifosfonatos (OMB) tem sido descrita desde 2003 como um efeito adverso dos medicamentos bifosfonatos. Essas drogas atuam sobre a vascularização e remodelação óssea, principalmente na atividade osteoclástica, podendo gerar áreas de exposição óssea necrótica. O tratamento para a doença ainda não é definido, mas o tratamento cirúrgico é uma das formas preconizadas que, em algumas situações podem ocasionar deformações orais como as comunicações buco-sinusais. Em situações como esta o tecido adiposo bucal é uma alternativa importante para o recobrimento da comunicação oro-nasal, devido ao seu grande suprimento sanguíneo, elasticidade, ausência de restrição pela idade e segurança. Este trabalho apresenta um caso clínico de paciente de 58 anos do sexo feminino, portadora de OMB em maxila esquerda pelo uso de ácido zoledrônico para câncer metastático. A extensa remoção da porção óssea necrótica resultou em fístula buco-sinusal. O retalho do tecido adiposo bucal foi utilizado para cobrir o defeito. Mais estudos devem ser realizados com relação ao tratamento de OMB, no entanto, se necessário, o retalho de tecido adiposo bucal poderia ser uma alternativa para resolver a comunicação oro-nasal relacionada à OMB.
Тема - темы
Humans , Female , Middle Aged , Bisphosphonate-Associated Osteonecrosis of the Jaw/surgery , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Imidazoles/adverse effects , Surgical FlapsРеферат
Os bisfosfonatos são medicamentos amplamente e efetivamente utilizados para o tratamento de doenças osteolíticas. Entretanto, na cavidade oral, é de particular relevância, pois possuem como efeito adverso a osteonecrose dos maxilares induzida pelo uso de bisfosfonatos. Sua etiopatogenia ainda não é bem estabelecida, os métodos de detecção são insatisfatórios e as terapias recomendadas são por vezes, medidas paliativas e ineficazes. Pouco ainda é sabido sobre o efeito do Ácido Zoledrônico na microestrutura óssea, portanto, propusemo-nos a realizar um estudo em modelo animal que analisasse o trabeculado ósseo da mandíbula através da Micro-CT. Foram utilizados 24 ratos machos (Rattus novergicus, albinus, Wistar), com 12 semanas de vida, divididos em 2 grupos: grupo controle (cloreto de sódio 0,9%) e grupo ácido zoledrônico (ácido zoledrônico 0,6mg/kg). As substâncias foram administradas via intraperitoneal a cada 28 dias em um total de 5 doses. Após 150 dias do início do experimento, foi realizada a eutanásia dos animais e então as amostras foram preparadas e escaneadas (Skyscan 1174) para análise da microestrutura óssea através da Micro- CT. O teste t-student demonstrou diferença estatisticamente significativa (p<0,05) em todos os fatores: volume ósseo, densidade óssea, fator de padrão trabecular, índice de modelo estrutural, espessura trabecular, separação trabecular, porosidade total exceção de número de trabéculas e volume tecidual, demonstrando que há alterações significativas na estrutura trabecular pelo uso de bisfosfonatos. O grupo medicado com ácido zoledrônico comparado ao grupo controle demonstrou trabéculas mais espessas, menos separadas e com menores ligações...
Bisphosphonates are widely and effectively drugs used for the treatment of osteolytic disorders. However, in the oral cavity, this situation is of particular relevance as it can lead to bisphosphonate related osteonecrosis of the jaws. Its etiopathogenesis is still not established, detection methods are unsatisfactory and recommended therapies are sometimes palliative and often ineffective. Little is known about the effect of zoledronic acid on the quality of trabecular bone, therefore, we proposed to conduct a study in an animal model to examine the trabecular bone of the jaw through the Micro-CT. 24 male rats were used (Rattus norvegicus, Albinus, Wistar), with 12 weeks old, divided into 2 groups: control group (sodium chloride 0.9%) and group with zoledronic acid (zoledronic acid 0.6 mg / kg). The substances were administered intraperitoneally every 28 days for a total of 5 doses. After 150 days from the beginning of the experiment, the animals were sacrificed and then the samples were prepared and scanned (Skyscan 1174) for analysis of the bone microstructure through Micro-CT. The "t-student" test demonstrated statistically significant differences (p<0.05) in all factors: bone volume, osseous density, trabecular pattern, structure model index, trabecular thickness, trabecular separation, total porosity except trabecular number and tissue volume, demonstrating that there are significant changes in the trabecular structure of the bisphosphonates. Zoledronic Acid compared to control group shows thicker, less separate and lower connected trabeculae...
Тема - темы
Animals , Male , Rats , Bisphosphonate-Associated Osteonecrosis of the Jaw , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Imidazoles/adverse effects , Mandible , Bisphosphonate-Associated Osteonecrosis of the Jaw , Bone Density , Mandible/pathology , Rats, Wistar , Tomography, X-Ray ComputedРеферат
Zoledronic acid has been used for prevention of osteolytic and osteoblastic bone metastasis. This case report illustrates an undesirable consequence from prolonged usage of zoledronic acid in bone metastasis prevention. Periprosthetic acetabular fracture in a patient treated with zoledronic acid for 7 years was reported. The clinical presentation, radiographic and pathological results were described. This is a rare complication after total hip arthroplasty which should not be ignored especially in patients who received long term bisphosphonate.
Тема - темы
Aged , Female , Humans , Acetabulum/injuries , Arthroplasty, Replacement, Hip/adverse effects , Bone Density Conservation Agents/adverse effects , Bone Neoplasms/prevention & control , Bone Remodeling/drug effects , Breast Neoplasms/pathology , Diphosphonates/adverse effects , Fractures, Spontaneous/chemically induced , Hip Prosthesis , Imidazoles/adverse effects , Osteoarthritis, Hip/surgery , Periprosthetic Fractures/chemically induced , Prosthesis Failure , ReoperationРеферат
Introdução: os bifosfonatos são um grupo de medicamentos utilizados no tratamento de doenças malignas metastáticas e em outras doenças ósseas como osteoporose e doença de Paget. Seu mecanismo de ação reduz a reabsorção óssea, a inibição do recrutamento e promoção da apoptose de osteoclastos. Apesar dos grandes benefícios para pacientes nestas condições, uma complicação associada ao seu uso é aosteonecrose dos maxilares. Objetivo: relatar um caso clínico envolvendo um paciente do sexo masculino de 72anos, sob tratamento endovenoso mensal com ácido zoledrônico, que evoluiu com osteonecrose espontânea bilateral em região posterior mandibular após um ano sob uso desta medicação. Conclusão: a conscientização dos Cirurgiões Dentistas quanto à etiologia da osteonecrosee a manutenção de ótima higiene oral nos pacientes sob uso destes medicamentos são fundamentais na prevenção da ocorrência desta condição.
Introduction: Biphosphonates are a group of drugs used to treat metástases associated with breast or prostate cancer and other bone diseases, including osteoporosis and Paget disease. They inhibit bone resorption through na action on osteoclasts slowing their activity and inducing apoptosis. Despite the benefits of biphosphonates, osteonecrosis of the jaw (ONJ) has emerged as a serious complication in some patients treated with these drugs. Aim: a case report of a 72-year-old male treated with zoledronic acid for one year that presented spontaneous bilateral ONJ is presented. Conclusion: the awareness of the dentists regarding the etiology of the ONJ and the maintenance of a great oral hygine by the patients under these medications are essencial for preventing this condition.
Тема - темы
Humans , Male , Aged , Bisphosphonate-Associated Osteonecrosis of the Jaw , Diphosphonates/adverse effects , Mandibular Diseases/chemically induced , Imidazoles/adverse effects , Bisphosphonate-Associated Osteonecrosis of the Jaw , Mandibular Diseases/pathology , Radiography, PanoramicРеферат
Objetivos Determinar los posibles resultados negativos asociados a la medicación mediante la metodología de búsqueda activa de posibles interacciones medicamentosas en bases de datos de pacientes afiliados al Sistema General de Seguridad Social en Salud. Métodos A partir de las bases de datos de dispensación de medicamentos de Audifarma S.A a unos 4 millones de usuarios del país, se hizo una revisión sistemática de estadísticas de una serie de medicamentos identificados por presentar interacciones de riesgo, dosis diferentes a las recomendadas o dispensación irregular. Los casos son socializados con las EPS responsables. Resultados Se encontró un caso de nefrotoxicidad por ácido zoledrónico; el 37,0 por ciento de los usuarios de clopidogrel recibían concomitantemente omeprazol, que reduce la efectividad del primero; el 29,9 por ciento de los pacientes que toman losartan están recibiendo dosis superiores a las recomendadas para su indicación; el 2,0 por ciento de los pacientes que toman metoprolol o verapamilo, los recibe simultáneamente, con riesgo de generar bradicardia sinusal, bloqueos auriculoventriculares o disfunción sistólica. Todos los casos fueron notificados a los responsables en la EPS que atienden estos pacientes. Discusión La farmacovigilancia activa permite optimizar recursos, prevenir eventos adversos que puedan potencialmente causar morbilidad importante o incluso letalidad o determinar problemas que podrían ser responsables del fracaso terapéutico. Este tipo de estrategia se anticipa a la aparición de posibles riesgos para el paciente por lo que se recomienda considerarla para reforzar los programas de vigilancia de uso de medicamentos en el país.
Objectives Determining negative results associated with medication through an active search of possible drug interactions in databases for patients affiliated to the Colombian general social security/health system. Methods Statistics related to Audifarma S.A. dispensation drug databases for about 4 million Colombian users were systematically reviewed for identifying drugs having known interactions involving risk, doses different from recommended ones or irregular dispensation. The pertinent health-care providing services were made aware of the above. Results There was one case of nephrotoxicity being caused by zoledronic acid. 37 percent of clopidogrel users concomitantly received omeprazole which reduces the former's effectiveness. 29.9 percent of patients who were taking losartan were receiving doses higher than the recommended ones. 2.0 percent of patients who were taking metoprolol or verapamil were simultaneously receiving them, at the risk of generating first-degree heart block, bradycardia, or systolic dysfunction. All these cases were notified to the pertinent health-care services. Conclusions Active pharmacosurveillance leads to resources being optimised, adverse events which can potentially cause morbidity or lethality being prevented or even determining problems which could be responsible for therapeutic failure. This type of strategy anticipates the appearance of possible risks for patients, meaning that drug use monitoring programmes in Colombia should be reinforced.
Тема - темы
Humans , Adverse Drug Reaction Reporting Systems , Drug-Related Side Effects and Adverse Reactions/epidemiology , Medication Systems/statistics & numerical data , National Health Programs/statistics & numerical data , Adverse Drug Reaction Reporting Systems/organization & administration , Adverse Drug Reaction Reporting Systems/statistics & numerical data , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/adverse effects , Calcium Channel Blockers/pharmacokinetics , Colombia , Diphosphonates/adverse effects , Drug Interactions , Imidazoles/adverse effects , Losartan/adverse effects , Medication Systems/organization & administration , Metoprolol/administration & dosage , Metoprolol/adverse effects , Metoprolol/pharmacokinetics , Omeprazole/administration & dosage , Omeprazole/pharmacokinetics , Retrospective Studies , Social Security , Software , Ticlopidine/administration & dosage , Ticlopidine/adverse effects , Ticlopidine/analogs & derivatives , Ticlopidine/pharmacokineticsРеферат
FUNDAMENTO: As diretrizes nacionais e internacionais enfatizam a importância do tratamento eficaz da hipertensão arterial. Apesar disso, verificam-se baixos índices de controle e alcance das metas preconizadas, indicando que é importante planejar e implementar melhores estratégias de tratamento. OBJETIVO: Avaliar a eficácia de um tratamento, em escalonamento de doses, tendo como base a olmesartana medoxomila. MÉTODOS: Este é um estudo aberto, nacional, multicêntrico e prospectivo, de 144 pacientes com hipertensão arterial primária nos estágios 1 e 2, virgens de tratamento ou após período de washout de duas a três semanas para aqueles em tratamento ineficaz. Avaliou-se o uso da olmesartana medoxomila num algoritmo de tratamento, em quatro fases: (i) monoterapia (20 mg), (ii-iii) associada à hidroclorotiazida (20/12,5 mg e 40/25 mg) e (iv) adição de besilato de anlodipino (40/25 mg + 5 mg). RESULTADOS: Ao fim do tratamento, em escalonamento, 86 por cento dos sujeitos de pesquisa alcançaram a meta de pressão arterial (PA) < 130/85 mmHg. Ocorreram reduções na pressão arterial sistólica (PAS) e na pressão arterial diastólica (PAD) de, no máximo, -44,4 mmHg e -20,0 mmHg, respectivamente. A taxa dos respondedores sistólicos (PAS > 20 mmHg) foi de 87,5 por cento e diastólicos (PAD > 10 mmHg) de 92,4 por cento. CONCLUSÃO: O estudo se baseou em um esquema de tratamento semelhante à abordagem terapêutica da prática clínica diária e mostrou que o uso da olmesartana medoxomila, em monoterapia ou em associação a hidroclorotiazida e anlodipino, foi eficaz para o alcance de meta para hipertensos dos estágios 1 e 2.
BACKGROUND: The national and international guidelines emphasize the importance of the effective treatment of essenssial hypertension. Nevertheless, low levels of control are observed, as well as low attainment of the recommended goals, indicating that it is important to plan and implement better treatment strategies. OBJECTIVE: To evaluate the efficacy of a based treatment algorithm with olmesartan medoxomil. METHODS: This is an open, national, multicentric and prospective study of 144 patients with primary arterial hypertension, stages 1 and 2, naïve to treatment or after a 2-to-3 week washout period for those in whom treatment was ineffective. The use of olmesartan medoxomil was assessed in a treatment algorithm divided into 4 phases: (i) monotherapy (20 mg), (ii-iii) associated to à hydrochlorothiazide (20/12.5 mg and 40/25 mg) and (iv) addition of amlodipine besylate (40/25 mg + 5 mg). RESULTS: At the end of the phased-treatment, 86 percent of the study subjects attained the goal of BP < 130/85 mmHg. Maximum reductions in SAP and DAP were -44.4 mmHg and -20.0 mmHg, respectively. The rate of systolic responders (SAP > 20 mmHg) and of diastolic responders (DAP > 10 mmHg) was 87.5 percent and 92.4 percent, respectively. CONCLUSION: The study was based on a treatment regimen that was similar to the therapeutic approach in daily clinical practice and showed that the use of olmesartan medoxomil in monotherapy or in association with hydrochlorothiazide and amlodipine was effective in the attainment of the recommended goals for hypertension stage 1 and 2 hypertensive individuals.
Тема - темы
Adult , Aged , Female , Humans , Male , Middle Aged , Algorithms , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Antihypertensive Agents/therapeutic use , Hypertension/drug therapy , Imidazoles/therapeutic use , Tetrazoles/therapeutic use , Amlodipine/adverse effects , Amlodipine/therapeutic use , Angiotensin II Type 1 Receptor Blockers/adverse effects , Antihypertensive Agents/adverse effects , Drug Therapy, Combination , Hydrochlorothiazide/adverse effects , Hydrochlorothiazide/therapeutic use , Imidazoles/adverse effects , Prospective Studies , Reference Values , Severity of Illness Index , Treatment Outcome , Tetrazoles/adverse effectsРеферат
The possible modulatory effects of thymoquinone [TQ] against pathological changes induced by imidacloprid [IC] were examined using male albino rats. One hundred and forty four adult male albino rats [Rattus norvegicus] were allocated into six groups, one group is normal, two are control groups and the other are treated groups. IC was given orally at a dose of 1/100 LD 50/ day for 4 weeks, without TQ, before TQ, or with TQ [given as a single i.p. injection weekly at a dose of 1 mg/ kg.b.wt]. Histopathological studies of liver showed dense interstitial hemorrhage, pyknotic nuclei, and infiltration with leucocytes. Also, kidney sections of animals treated with IC insecticide showed clear proliferation, interstitial hemorrhage, and pyknotic nuclei in glomerular tissue. Furthermore, marked dilatation in renal tubules and urinary spaces were observed. Medullary tubules of the kidney showed interlobular hemorrhage. Partial recovery of histological changes was observed after TQ supplementation. It is concluded that TQ might alleviate histological alteration in the liver and kidney which are induced by IC
Тема - темы
Animals, Laboratory , Animals , Receptors, Nicotinic/toxicity , Insecticides , Rats , Protective Agents , Nigella sativa , Liver/pathology , Kidney/pathology , Histology , Imidazoles/adverse effects , Imidazoles/toxicityРеферат
PURPOSE: The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metastasis was evaluated in patients with hormone-refractory prostate cancer. PATIENTS AND METHODS: A total of 19 hormone-refractory prostate cancer patients with bone metastases were enrolled. All patients received up to six infusions of zoledronic acid (4mg, given intravenously over 15 minutes, every 3-4 weeks). Safety was assessed by monitoring a`dverse events and serum creatinine levels. Efficacy was assessed by monitoring skeletal-related events, brief pain inventory score, quality of life score, type of pain medication, and analgesic score. Mean age of patients was 67.3 years (46-86 years), mean time from diagnosis of bone metastases was 27.6 months (0-117 months), and mean time from diagnosis of hormone-refractory disease was 7.5 months (0-26 months). RESULTS: There was no clinically significant change in serum creatinine levels. Eleven adverse events (musculoskeletal disorders and systemic disorders) in 8 patients were classed as having a possible relationship to study drug. Fifteen patients completed six courses of zoledronic acid infusion. There were no significant changes in the brief pain inventory composite scores, quality of life questionnaire scores or analgesic score. No new skeletal-related events developed during the treatment period. CONCLUSION: Zoledronic acid administered in this study as a 15-minute infusion demonstrated an acceptable and well-known safety profile in patients with refractory prostate cancer with bone metastases. However, prospective placebo- controlled clinical trials are required to elucidate the efficacy of zoledronic acid.
Тема - темы
Aged , Aged, 80 and over , Humans , Male , Middle Aged , Antineoplastic Agents, Hormonal/therapeutic use , Bone Density Conservation Agents/adverse effects , Bone Neoplasms/drug therapy , Creatinine/blood , Diphosphonates/adverse effects , Drug Resistance, Neoplasm , Imidazoles/adverse effects , Prospective Studies , Prostatic Neoplasms/drug therapy , Quality of Life , Treatment OutcomeРеферат
Biphosphonates reduce the risk of skeletal events and are currently part of standards of therapy in myeloma. Recently, zoledronate and pamidronate have been linked to osteonecrosis of the jaw, specially after surgical dental procedures. We report a 84 year-old man with multiple myeloma who developed spontaneous osteonecrosis of both jaws, after 36 months of therapy with zoledronate with a cumulative dose of 136 mg. We discuss the pathogenic mechanisms, and review the recommendations on prevention and management of this new complication for neoplastic patients under prolonged therapy with biphosphonates.
Тема - темы
Aged, 80 and over , Humans , Male , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Imidazoles/adverse effects , Jaw Diseases/chemically induced , Multiple Myeloma/drug therapy , Osteonecrosis/chemically induced , Jaw Diseases/pathology , Osteonecrosis/pathologyРеферат
Rilmenidine is proposed as a selective imidazoline receptor rather than [2 adrenoreceptor drug. It was reported that rilmenidine causes marked centrally-mediated hypotension, whilst the incidence of its adverse effects is quite low. Clonidine is another centrally acting antihypertensive agent characterized by its wide therapeutic range. The mechanism of its antihypertensive action appears to be through stimulation of postsynaptic [2-adrenergic receptors in the nucleus tractus solitari of the medulla oblongata. The present study aimed to investigate: [1] The antihypertensive effect of rilmenidine 1mg/kg i.v versus that of clonidine 0.03mg/kg i.v in experimentally induced-hypertension in rats by renal artery occlusion. [2] Study the possible sedative effect of rilmenidine 10mg/kg i.p versus that of clonidine 0.25mg/kg i.p. [3] Evaluate the effect of yohimbine 10mg/kg i.v on rilmenidine and clonidine actions. The results of the present study revealed that at equipotent doses; both rilmenidine and clonidne induced a transient significant [p<0.05] elevation of blood pressure followed by long-lasting hypotension and bradycardia. It was also found that yohimbine significantly [p<0.05] blocked the antihypertensive effect of clonidine but produced insignificant [p>0.05] effect on rilmenidine hypotensive action. On the other hand, rilmenidine had insignificant [p>0.05] effect on sleeping time induced by pentobarbitone 30 mg/kg i.p, whilst clonidine produced significant [p<0.05] increase in the sleeping time, an action which was significantly [p<0.05] attenuated by yohimbine. In conclusion, rilmenidine proved to has high efficacy as an antihypertensive drug with less sedative side effects compared with clonidine. This may be due to its main action on the central imidazoline receptors rather than on the alpha[2] adrenoceptors
Тема - темы
Male , Animals, Laboratory , Imidazoles/adverse effects , Clonidine/adverse effects , Conscious Sedation , Rats , Models, Animal , Treatment OutcomeРеферат
Pesticide use in Costa Rica is very high and all year round. A high percentage of what is sprayed remains in the environment and in the living organisms around. This situation brings contamination and health problems to people in contact with them. The onset of adverse effects may be in the short or the long term, and symptoms vary widely, from headaches to cancer. Much research in this area has been devoted to acute or chronic effects, and not until recently to the genotoxic effect of pesticides. This study evaluated the genotoxic effect of pesticides used in banana packing activities, using the comet assay (single cell electrophoresis) as the biological marker in lymphocytes. This was a case-control double blind study of 30 exposed women from 15 banana farms and 28 women not occupationally exposed to pesticides from the same geographic area. Results show damage to single stranded DNA after working from 5 to 15 years (R2 = 0.12). In Costa Rica we do not have an historical record of the kind of pesticides used in banana farms, the period of time and for how long were they used. This prevented further analysis concerning dose, frequency of exposure and use of new or old kind of pesticides in the farms in relation to DNA damage. The comet assay is of value in the genetic monitoring of pesticide exposed populations.